TELA - NASDAQ

TELA Bio, Inc.

TELA·NASDAQ

$1.14

+0.44%

HealthcareMedical - Devices

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.78M

EPS-0.8300

P/E Ratio-1.37

Earnings Date05/06/2026

81.42M

Assets

-7%

3Y+20.0%

5Y-6.0%

10Y+424.0%

75.11M

Total Liabilities

28%

3Y+40.0%

5Y+101.0%

10Y-39.0%

6.31M

Total Equity

-78%

3Y-56.0%

5Y-87.0%

10Y-106.0%

TELA Bio, Inc. Funding & Solvency Profile

TELA · NASDAQ

Current Assets

Cash & Cash Equivalents50.84M

Net Receivables10.35M

Inventory11.02M

Other Current Assets3.37M

Total Current Assets76 M

Non-Current Assets

Property, Plant & Equipment3.73M

Goodwill & Intangible Assets1.36M

Long-Term Investments250.00K

Other Non-Current Assets500.00K

Total Non-Current Assets4 M

Total Assets

81.42M

Financial Health Analysis

Current Ratio

4.20x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

11.90x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

58 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

93% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

TELA Bio, Inc. Balance Sheet

TELA • NASDAQ

TELA Bio, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	50.8M	52.7M	46.7M	42M	43.9M	74.4M	45.3M	17.3M	11.3M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	9.3M	0.0	0.0
Cash & Short-Term Investments	50.8M	52.7M	46.7M	42M	43.9M	74.4M	54.6M	17.3M	11.3M
Net Receivables	10.3M	10.1M	9.7M	6.6M	4.2M	2.7M	2.8M	1.3M	757K
Accounts Receivables	10.3M	10.1M	9.7M	6.6M	4.2M	2.7M	2.8M	1.3M	757K
Inventory	11M	12.8M	13.2M	11.8M	7.7M	3.9M	4.6M	4.3M	1.8M
Prepaids	0.0	0.0	0.0	0.0	3.2M	2.2M	2.3M	330K	429K
Other Current Assets	3.4M	2.5M	2.1M	2M	0.0	0.0	0.0	0.0	0.0
Total Current Assets	75.6M	78.1M	71.7M	62.4M	59.1M	83.2M	64.3M	23.3M	14.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.7M	4.1M	3.9M	2.9M	1.2M	626K	677K	758K	1.2M
Intangible Assets	1.4M	1.7M	2.1M	2.5M	2.3M	2.6M	2.9M	3.2M	0.0
Goodwill & Intangible Assets	1.4M	1.7M	2.1M	2.5M	2.3M	2.6M	2.9M	3.2M	0.0
Long-Term Investments	250K	2.5M	265K	0.0	0.0	0.0	0.0	0.0	24K
Tax Assets	0.0	896K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	5.8M	9.3M	6.3M	5.4M	3.5M	3.2M	3.6M	4M	1.2M
Total Assets	81.4M	87.3M	78M	67.9M	62.5M	86.5M	67.9M	27.2M	15.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.3M	2.1M	1.7M	1.5M	2.4M	652K	3.2M	3.4M	1.5M
Accounts Payable	2.3M	2.1M	1.7M	1.5M	2.4M	652K	3.2M	3.4M	1.5M
Accrued Expenses	0.0	7.3M	9.2M	6.4M	5M	3.7M	2.4M	5.2M	1.8M
Short Term Debt	0.0	545K	565K	340K	0.0	0.0	0.0	0.0	905K
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6M
Other Current Liabilities	15.7M	5.6M	5.5M	4.1M	3.2M	2.2M	1.2M	985K	1.9M
Total Current Liabilities	18M	15.6M	17M	12.4M	10.6M	6.6M	6.7M	9.6M	6.1M
NON-CURRENT LIABILITIES
Long Term Debt	55.7M	41.1M	40.5M	39.9M	31.5M	30.8M	30.2M	29.7M	3.6M
Deferred Tax Liabilities (Non-Current)	0.0	756K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	1.5M	0.0	0.0	31K	380K	0.0	4K	125.8M	113.9M
Total Non-Current Liabilities	57.1M	43.3M	42.2M	41.1M	31.9M	30.8M	30.2M	155.5M	117.6M
Capital Lease Obligations	0.0	1.4M	1.7M	1.2M	0.0	0.0	0.0	0.0	0.0
Total Liabilities	75.1M	58.9M	59.2M	53.6M	42.4M	37.4M	37M	165.1M	123.7M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	67.9M	124.2M	111.3M
Common Stock	44K	39K	24K	19K	15K	14K	11K	0.0	7K
Additional Paid-In Capital	403.7M	387.1M	339.7M	288.4M	250.1M	245.7M	198.8M	0.0	0.0
Retained Earnings	-397.6M	-358.7M	-320.9M	-274.2M	-229.9M	-196.7M	-167.9M	-137.9M	-108.2M
Accumulated Other Comprehensive Income/Loss	91K	90K	91K	150K	-52K	-71K	-19K	-3.2M	-2.8M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2M	-108.6M
Total Stockholders' Equity	6.3M	28.5M	18.9M	14.3M	20.1M	49M	31M	-137.9M	-108.2M
Total Equity	6.3M	28.5M	18.9M	14.3M	20.1M	49M	31M	-137.9M	-108.2M
SUMMARY
Total Liabilities & Equity	81.4M	87.3M	78M	67.9M	62.5M	86.5M	67.9M	27.2M	15.5M
Total Investments	250K	2.5M	265K	0.0	0.0	0.0	9.3M	0.0	24K
Total Debt	55.7M	43.1M	42.8M	41.5M	31.5M	30.8M	30.2M	29.7M	4.5M
Net Debt	4.8M	-9.6M	-4M	-563K	-12.4M	-43.6M	-15.1M	12.5M	-6.8M
Shares Outstanding	39,616,400	39,616,400	39,616,400	39,616,400	39,616,400	39,616,400	39,616,400	39,616,400	39,616,400

SEC Filings

TELA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 30, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 09, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 17, 2026	2026	View Filing
S-3 S-3 N/A	December 12, 2025	December 12, 2025		View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 03, 2025	October 31, 2025	2025	View Filing

Showing 1 to 10 of 123 filings

Related Guides

Blog Categories

Continue your TELA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.